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Abstract
We demonstrate the first use of the nullomer (absent sequences) approach to drug discovery and development.
Nullomers are the shortest absent sequences determined in a species, or group of species. By identifying the
shortest absent peptide sequences from the NCBI databases, we screened several potential anti-cancer peptides.
In order to improve cell penetration and solubility we added short poly arginine tails (5Rs), and initially
solubilized the peptides in1M trehalose. The results for one of the absent sequences 9R (RRRRRNWMWC),
and its scrambled version 9S1R (RRRRRWCMNW) are reported here. We refer to these peptides derived from
nullomers as PolyArgNulloPs. A control PolyArgNulloP, 124R (RRRRRWFMHW), was also included. The
lethal effects of 9R and 9S1R are mediated by mitochondrial impairment as demonstrated by increased ROS
production, ATP depletion, cell growth inhibition, and ultimately cell death. These effects increase over time
for cancer cells with a concomitant drop in IC-50 for breast and prostate cancer cells. This is in sharp contrast to
the effects in normal cells, which show a decreased sensitivity to the NulloPs over time.

1. Introduction
This study investigates the biological properties of the smallest absent peptides, nullomer peptides
(NulloPs). These peptides were identified after a search of the NCBI databases, which counted all occurrences
of peptide strings, and generated a list of the smallest peptide sequences (currently length-5 amino acids) absent
from natural databases. While combinatorial and phage display libraries have been used to generate peptide
drugs that were not derived from nature, we have taken a completely new approach to look for effective cancer
drugs; we look specifically for what does not exist [21] in nature. Acquisti et al. have dismissed this approach
[1], claiming that absent sequences are actually a consequence of mutation and will not be useful for medical or
labeling purposes; but others have explored the distribution of absent sequences suggesting possible
applications [7,31,42]. We have used a new algorithm for this negative in-silico selection that enables us to
identify small epitopes with possible lethal effects [21]. While others have debated whether this approach might
yield lethal sequences [5,42], we have now shown that several of these peptides are in fact lethal at micromolar
concentrations. Our approach originally generated hundreds of NulloPs (unpublished data), and we have been
characterizing their biological effects, seeking to exploit their killing mechanisms to ultimately produce new
anticancer peptides. This report focuses on NulloP 9 (NWMWC), its scrambled version 9S1 (WCMNW); and
NulloP 124 (WFMHW). To ensure cell penetration we conjugated the NulloPs with PolyArg (RRRRR).
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Cancer therapy is a combination of surgery, chemotherapy, radiotherapy and recently growth factors and
cytokines, and has not yet met our dreams of curing this disease [2]. In spite of the application of a wide variety
of drugs, anti cancer chemotherapy has always been limited by side effects and chemoresistance [41]. The
extreme genetic adaptability of cancer cells in their ultimate quest of immortality and independence gives these
cells several survival advantages in harsh conditions; for example they can stop cell division and enter a state of
dormancy, or become stem cells capable of regenerating the original tumor [27].
Cancer cells are resistant to apoptosis induction, and a new paradigm in cancer therapy is emerging. Cancer
cells survive because their metabolism is altered with significant changes in mitochondrial function, and a lower
dependence on pyruvate oxidation, the Warburg effect [6]. The therapeutic approach known as mitochondrial
medicine [11,12,16] is justified for several reasons: cancer mitochondria have low oxidative phosphorylation,
high Δψm and reactive oxygen species (ROS) output, and a deregulated apoptotic pathway [12]. The
mitochondrial outer membrane permeabilization (MOMP) constitutes a “point of no return,” in that once it
begins, cells are destined to die by apoptosis or necrosis [29]. Chemicals targeting the mitochondria have the
advantage to initiate the MOMP independently of upstream signals that are frequently impaired in cancer cells,
and thus bypass chemoresistance [12,16].
Already many chemicals and peptides (derived from existing proteins involved in cell death) that target the
intrinsic mitochondrial death machinery are being used in clinical trials [12,16]. Other natural peptides such as
defensins [10,39,53] (endogenous antimicrobial peptides produced by leukocytes and epithelial cells), have
demonstrated anticancer potential. Their mechanism of action involves a stimulation of the immune system
[10,56], but it is still not clear what makes cancer cells susceptible to these peptides. The general mechanisms
suggested are: lysis of cancer cells [49,23], plasma membrane disruption via micellization or pore formation
[50], and induction of apoptosis via mitochondrial membrane disruption [48].
One of the characteristics of the NulloPs described here is their high hydrophobicity due to the presence of
TRP and MET. Their poor solubility in water becomes a major obstacle for their use. In order to overcome this,
we fused them to a cell penetrating peptide (CPP). This is a well established approach that started with the
observation that the human immunodeficiency virus 1 (HIV-1) Tat protein can enter cells efficiently in vitro
[13]. In 1997, Vives et al. [51] discovered that an 11 amino acids sequence, Tat 48-60 (GRKKRRQRRRPPQ)
known as the Tat peptide, can enter cells more efficiently than the full length Tat protein. A PolyArg peptide
made from 6 to 9 L-ARG maintains the same cell penetrating capacity as the original Tat peptide [52]. The
mechanism(s) of internalization of PolyArg CPP is still a controversial matter. There are two principal routes of
internalization: endocytosis (an energy dependent process), and transduction through cellular membrane.
PolyArg CPP [45] and Tat protein [36] interact with the cell membrane by inducing a Gaussian membrane
curvature as a prelude to pore formation through which transduction to the cytosol occurs. In spite of the pore
formation, after transduction of PolyArg CPP and its cargo inside the cell, the cell membrane integrity is not
compromised and the cell remains negative for propidium iodide (PI) staining [37]. The release of the cargo
from the PolyArgCPP-Cargo complex has not yet been demonstrated [34].
We have proposed that by identifying the smallest absent DNA sequences, we can find short peptides
eliminated by natural selection. These sequences may have unusual properties that can be exploited for drug
development [21]. This report demonstrates the anticancer benefits of the nullomer approach, and shows that
NulloPs can affect the growth of several cancer cell lines by mitochondrial impairment.
2. Methods
2.1 Cell culture
Cell lines used in this study were obtained from the American Type Culture Collection (ATCC, Manassas,
VA). The human and murine cancer lines are: LnCap (CRL-1740) derived from a human prostate carcinoma,
2	
  
NOTICE: this is the author's version of a work that was accepted for publication in Peptides. Changes resulting from the publishing process, such as peer review, editing, corrections,
structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication.
A definitive version was subsequently published in Peptides, 2012. DOI: 10.1016/j.peptides.2012.09.015

MDA-MB-231 (HTB-26) derived from a human breast adenocarcinoma, B16 (CRL-6322) derived from a
C57BL/6J mouse skin melanoma, HUT102 (TIB-162) derived from an ATL (HTLV-1 Adult T cell Leukemia)
a gift from Dr. T.A. Waldmann (NIH/NCI ), J774A.1 (TIB-67) mouse monocyte/macrophage derived from a
BALB/cN reticulum cell sarcoma. Primary normal cell lines were used as well: PCS (PCS-440-010) normal
primary prostate epithelial cells, HMEC (ECACC-HMEC 830-05a) normal human mammary cells, WI-38
(CCL-75) human embryonic fibroblasts derived from a 3 months gestation fetus. LnCap, MDA-MB-231, and
HUT102 were cultured in RPMI 1640 supplemented with 10% Hyclone Fetal Bovine Serum (FBS) and 1X
Penicillin Streptomycin (100X solution, Invitrogen). B16 and WI-38 were cultured in DMEM supplemented
with 10% Hyclone FBS and 1X Penicillin Streptomycin. PCS cells were cultured in the Prostate Epithelial Cell
Basal Medium (PCS-440-030) supplemented with the Prostate Epithelial Cell Growth Kit (PCS-440-040).
HMEC cells were cultured in the Clonetics MEGM BulletKit (CC-3150). Cell cultures were incubated at 37ºC
and 5% CO2. For PCS and HMEC cells we used passages 2-4. The passaging of cells was done at 80%
confluence; after a PBS wash, cells were treated with Trypsin-EDTA 0.25% (Invitrogen). Cells were seeded in
96 well plates (Costar) and allowed to adhere to the surface overnight, then the old media was removed and
replaced with 90 µl fresh media, with 10 µl containing peptides or other treatment.
2.2 Cell viability assay
Cell viability was measured by the colorimetric MTT assay (Sigma, St Louis MO). 3000-5000 cells/well
were seeded in 96 well plates and exposed to peptides or other treatments. At each time point, the MTT solution
(5 mg/ml in PBS) was added directly to wells and incubated at 37°C for 4 h, then the formazan crystals
solubilized with 100 µl dimethyl sulfoxide (DMSO), and incubated for 1h at 37ºC. Absorbance at 570 nm was
taken by a plate reader (SynergyMx from Biotek, Winooski VT). Plate readings were exported to Microsoft
Excel and GraphPadPrism software. All the wells were analyzed in triplicates. The statistical analysis was done
with the GraphPadPRISM*.
2.3 PolyArg-peptides synthesis
The PolyArgNulloPs were made by Elim Biopharmacuticals (Hayward, CA) and Pierce Biotechnology
(Rockford, IL). HPLC purified peptides (purity >98%) were delivered in 1 to 2 mg/tube (lyophilized) format
and stored at -20°C. Peptides were solubilized in 1M trehalose to produce 100 mM stock solutions. Only freshly
prepared solutions were used to treat cells. Several concentrations of the peptides were used with a range from
5-10 µM to 100 µM. The trehalose concentration in all reactions was 1 mM (a dose without any effect on cell
growth).
2.4 Preparation for scanning electron microscopy
Cells were cultured as described above in 35 mm dishes containing cover slips. Cover slips were prefixed in
4% paraformaldehyde in PBS for 30 minutes (mn), washed in distilled water 3 times for 5 mn each and placed
in 2.5% glutaraldehyde for 30 mn, followed by washing in distilled water as described. Cover slips were then
placed in 0.5% osmium tetroxide for 30 mn and washed again in distilled water. Cover slips were then
transferred to 1% tannic acid for 30 minutes, washed in distilled water and transferred a second time to 0.5%
osmium tetroxide, and washed again in distilled water. Cover slips were dehydrated in ethanol (30%, 50%,
70%, 80%, 90% and 100% × 3), 5 mn each. The cover slips were transferred to a K850 critical point dryer
(Quorum Technologies, Ashford, UK) using 100% ethanol as the transitional fluid. Dried cover slips were
sputtered with gold (~20 nm) in a CrC150 sputter coater (Torr International, New Windsor, NY, USA), and
examined in a Hitachi S-3400N scanning electron microscope.
2.5 HCS Mitochondrial Health Assay
The HCS Mitochondrial Health Kit (Invitrogen, Carlsbad CA) uses two dyes: the MitoHealth stain
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(excitation/emission maxima 550/580 nm) accumulates in the mitochondria of live cells proportional to the
mitochondrial membrane potential, Hoechst 33342 (excitation/emission 350/461 nm) stains nuclear DNA in
live and dead cells. Cells were seeded in 96 well plates and incubated with peptides for 24h. Then 50 µl of
MitoHealth stain was added to each well and incubated for 30 mn. After removing the media, Hoechst 33342
and 3.7% paraformaldehyde were added to cells. After washing the cells twice with PBS, colorimetric reading
was taken with the plate reader. Relative fluorescence was measured in BioTek Synergy plate reader. This kit
was manufactured for imaging, but we standardized it with SynergyMx plate reader for reading 96-well plates.
2.6 Measurement of total cellular ATP content
Cells were seeded in 96 well plates (white plates from Nunc to block luminescence bleeding between the
wells) and allowed to attach for 24h. Then cells were incubated for 2h, 24h and 48h with peptides (1-50 µM of
9R, 9S1R and 124R), or 100mM sodium azide as an ATP depletion control [26] At each time point a single
reagent, Cell Titer GlowTM (Promega), was added to cells.. Complete reagent mixing in 96 wells plates required
gentle orbital shaking for 2-10 mn. The plate reading was taken by SynergyMx plate reader. Plate readings were
exported to Microsoft Excel and GraphPadPrism software. All the wells were analyzed in triplicates. The
statistical analysis was done with the GraphPadPRISM*.
2.7 Live/Dead assay
Each peptide’s effect on cell vitality was measured by the live/dead assay kit from Invitrogen (Carlsbad,
CA). This kit uses Hoechst 33342 as a nucleic acid stain (blue fluorescence) and PI (red fluorescence). Since PI
is not permeant to live cells, it is commonly used to detect dead cells in a population. The PI concentration used
in this study was 6.25µg/ml. After 2h incubation with PolyArgNulloPs, cells were stained directly in the
reaction media with these two stains, and fluorescent images were taken by Zeiss axiovert 40 microscope
(Oberkochen, Germany) using a SPOT imaging camera (Sterling Heights, MI).
2.8 Super Oxide Assay
After 24h incubation in 96 wells microplates, cells were treated with peptides or control for 2h. Then
MitoSOX™ red reagent (Invitrogen) was added for 10 mn, and washed with PBS. The final plate reading was
taken in SnyergyMX plate reader.
2.9 Hemolytic activity
The hemolytic activity of PolyArgNulloPs was determined on human red blood cells (RBCs) from healthy
volunteers. Blood samples were centrifuged and RBCs washed twice with PBS. A 10% RBCs suspension was
incubated with 10 µM, 25 µM and 100 µM of peptides (9R, 9S1R and 124R) at 37°C for 24 h with 100 rpm
shaking. PBS was used as a negative control (0% lysis: AControl), and 1% Triton X-100 as a positive control
(100% lysis: ATotal). After incubation the samples were centrifuged and supernatants transferred into a 96-well
plate to quantify RBCs lysis by a spectrophotometric reading at λ=405 nm [23]. The hemolytic activity [20] in
% was calculated using this formula: Hemolytic activity in %={[ASample-AControl]/[ATotal-AControl]}x100
2.10 Statistical analysis
All results are expressed as mean ± SE (standard error). The statistical analysis was done with the
GraphPadPRISM* version 5.03 using one-way analysis of variance (ANOVA) followed by a Tukey’s post test.
A p-value of less than 0.05 was considered statistically significant.
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3. Results
3.1 The in vitro effect of PolyArgNulloPs peptides on cell growth
Cells were exposed to different doses (10-100 µM) of PolyArgNulloPs (9R, 9S1R and 124R) for 2h, 24h
and 48h. For each time period, the exposure of cells to the peptides was continuous with no change of the
culture medium. The 2h time point was aimed at detecting toxic effects similar those of the control treatment
H2O2 (0.01%). The 24h and 48h time points were used to examine peptide effects related to the cell cycle.
The results show clearly that peptide 124R has no effect on the growth of LnCap prostate cancer
(Suppl.R1A) or MDA-MB-231 (Suppl.R1B) cells. Peptide 124R is a PolyArgNulloP with the same number of
amino acids, and the same poly Arginine content as 9R, 9S1R, and can be considered a control peptide. The
peptide 9R at 100 µM has a toxic effect at 2h on LnCap cells, similar to the effect of H2O2 (0.01%). At 24h and
48h, 9R has a moderate effect on LnCap at 20-30 µM, and an almost completely lethal effect at 50-100 µM.
However, we do not observe a classic dose dependent effect between 5-100 µM with 9R in LnCap cells. With
the MDA-MB-231 cells, peptide 9R produces a dose dependent effect (10-100 µM) at 2h, 24h and 48h. The
peptide 9S1R shows a dose dependent effect over 10-100 µM at 2h for both the LnCap (Suppl.R1A), and
MDA-MB-231 (Suppl.R1B) cells. This toxic effect is also seen at 24h and 48h.
The melanoma B16 cell line was included in this study because skin melanoma is the sixth most prevalent
cancer in North America, and its incidence is on the rise [14]. The three peptides 9R, 9S1R and 124R at doses
10-100 µM, and at time points from 2h to 96 h (Suppl.R1C), have no effect on the growth of B16 cells.
Peptide 124R, at doses 10-100 µM, at time points from 2h to 96h, has no effect on the growth of HUT 102
cells. However, peptide 9R and 9S1R have a toxic effect at 100 µM seen from 2h. In addition, a dose response
was observed from 10-100 µM at time points from 48h to 72h. In highest range of doses (50-100 µM), a dose
dependent effect is only observed at the 96h time point (Suppl.R1D).
The peptides 9R, 9S1R and 124R have no effect on the growth of J774A.1 cells at doses 10-100 µM, from
2h to 72h. At 96h, peptide 124R has no effect; but there is a dose dependent effect with 9R and 9S1R (although
the effect is more pronounced with 9R) (Suppl.R1E). Microscopically, the cells swell and contain many
vacuoles (data not shown).
We also examined the effects of the peptides 9R, 9S1R and 124R on normal cells. Peptide 124R has no
effect on the growth of WI-38 (Suppl.R1F), and PCS (Suppl.R1G) cells up to 48h time point (10-100 µM).
However at the highest concentration (100 µM) peptide 124R has an effect on the growth of HMEC cells
(Suppl.R1H) at 24h, and to a lesser extent at 48h. Peptide 9R and 9S1R have a moderate dose dependent effect
(20-100 µM) on WI-38 cells at 24h, and that effect is restricted to the 50-100 µM treatments at 48h
(Suppl.R1F). Peptide 9R and 9S1R have a moderate effect on the growth of PCS cells at 24h and 48h time
points (Suppl.R1G). In addition, peptides 9R and 9S1R have a dose dependent effect (10-100 µM) on the
growth of HMEC cells at the 24h and 48h time points (Suppl.R1H).
Scanning electron micrographs of LnCap and MDA-MB-231 cells treated with 9R (Fig. 1E, F, respectively)
and 9S1 (Fig 1G, H, respectively) for 48 hours (100 µM), show greatly reduced cell density compared to
untreated LnCap (Fig. 1A) and MDA-MB-231 (Fig. 1B) cultures. Cells treated with the control peptide 124R
(Fig 1C, c, D, d) appear similar to untreated cells (Fig. 1A, a, B, b). At higher magnification the morphology of
9R and 9S1 treated cells show substantial membrane damage including blebbing and tearing (Fig. 1e, f, g, h).
3.2 The IC-50 evolution of PolyArgNulloPs peptides in vitro
We calculated the IC-50 of peptides 9R, 9S1R and 124R at every time point where there is an effect on the
growth of cells. As shown in Table 1, the evolution of IC-50 for cancer cells is different from that seen in
normal cells. For LnCap cells, the 9R IC-50 starts high at the 2h time point (44±2.5 µM), and drops by 48h
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(28±1.6 µM). The same pattern of IC-50 evolution for 9R is seen in MDA-MB-231 cells, where the IC-50 is 39
±1.8 µM at 2h, and falls to 16±0.9 µM at the 48h time point. The same pattern can be seen with peptide 9S1R;
for LnCap cells the IC-50 starts at 26±1.3 µM at 2h and falls to less than 8±0.5 µM at the 48h time point. For
MDA-MB-231 cells, with 9S1R the IC-50 starts at 18±0.5 µM at the 2h time point, and drops to 10±0.3 µM at
the 48h time point. For HUT102 cells, the IC-50 for 9R starts at 93±2.3 µM at the 2h time point, and falls to
25±1.6 µM at 96h time point. This observation shows clearly that the cancer cells are more sensitive to 9R and
9S1R over time. Normal cells show an opposite pattern. For PCS and HMEC cells, the IC-50 for 9R, 9S1R and
even 124R rises with time. This means that the sensitivity of normal cells to 9R, 9S1R and 124R diminishes
with time, while the sensitivity of the cancer cells increases with time. The obvious potential clinical importance
of this finding needs to be validated in animal models.
3.3 PolyArgNulloPs effects on cellular ATP level
We studied the effects of peptides 9R, 9S1R and 124R on total cellular ATP content in LnCap and MDA-MB231 cells. Peptide 124R at doses 1-50 µM, for time points from 2h to 48h, has no effect on the cellular level of
ATP in LnCap and MDA-MB-231 cells (Fig. 2). This is consistent with the observation that peptide 124R does
not affect cell growth. Peptide 9R has a moderate effect at the 2h time point with 50 µM peptide in both cell
lines. This effect persists at the 24h time point. By 48h, there is a 50% and 65% reduction with 25 µM and 50
µM 9R (respectively), this latter effect is similar to that seen with our control 100 mM sodium azide. Peptide
9S1R at 50 µM almost completely shuts down ATP production in both cell lines (LnCap and MDA-MB-231)
by the 2h time point, an effect more drastic than the sodium azide control. This is a toxic effect similar to that of
anthrax toxin in J774A.1 cells [3,4]. In addition, at 25 µM peptide 9S1R reduces the ATP level by 50% at the
2h and 24h time points, and by 85% at the 48h time point. The effect is even more dramatic in LnCap cells,
where 9S1R at 48h produces a 50% reduction of ATP level at 5-10 µM.
3.4 PolyArgNulloPs effects on mitochondrial function
Mitochondrial Membrane Potential (MMP) is the driving force behind ATP production by the mitochondrial
respiratory chain. As shown in (Fig. 3a) and (Fig. 3b), peptide 124R has no effect on MMP at 24h in either the
LnCap or MDA-MB-231 cell lines. Peptide 9R at 50-100 µM reduces by 40% the MMP in both cell lines.
Peptide 9S1R has dramatic effects on MMP, producing a 40% reduction at 30-100 µM in LnCap cells. In
MDA-MB-231 the reduction of MMP is even more dramatic: 40% reduction at 20-30 µM, and 95% reduction
at 50-100 µM.
Superoxide free radicals production is indicative of mitochondrial damage. We investigated the ROS
production 2h after exposure to the PolyArgNulloPs, before any cellular mechanisms can scavenge these free
radicals. As shown in (Fig. 4a) and (Fig. 4b), for both LnCap and MDA-MB-231, peptide 124R at 10-100 µM
has no effect on the production of ROS. However, for both cell lines, peptide 9R at 50-100 µM produces more
free radicals than the control H2O2 (0.01%). Peptide 9S1 at 10-100 µM induces ROS production in a dose
dependent manner in LnCap cells, and produces a dramatic increase of ROS production at 100 µM in MDAMB-231 cells. It is noteworthy that 9R and 9S1R at 100 µM in both cell lines induces more ROS production
than the H2O2 (0.01%) treated cells.
3.5 Effects of PolyArgNulloPs on RBCs
It is well known that some peptides puncture the cell membrane of RBCs, and this side effect can limit their
therapeutic potential. We exposed the PolyArgNulloPs (10µM, 25µM and 100 µM) to human RBCs from
healthy donors for 24h at 37ºC. As shown in (Fig. 5), peptides 9R and 124R have no hemolytic effect on human
RBCs, and peptide 124R produces only 1% hemolysis at 100 µM. In contrast, peptide 9S1R has significant
hemolytic activity: 0.5% at 10 µM, 2.5% at 25µM, and 12% at 100 µM. The hemolytic activity of peptide 9S1R
may explain its rapid toxic effects at 2h.
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3.6 Live/Dead Assay
We performed this analysis at the 2h time point, and used PI as a marker of cell death. Only cells with
compromised membrane integrity become PI positive. As shown in (Suppl.R2A) and (Suppl.R2B), both cell
lines (LnCap and MDA-MB-231) exposed to H2O2 (0.01%) for 2h are nearly 100% PI positive. The untreated
cells are all PI negative. Cells treated with 100 µM of peptide 124R for 2h show few PI positive cells (less than
1%). Both cell lines exposed to peptide 9R at 10 µM or 50 µM for 2h show no effect on PI entry. At 100 µM
9R, both cell lines show significant cell death (30-40% become PI positive). 9S1R has stronger effects on both
cell lines, as 30-40% become PI positive with 50 µM 9S1R, and almost 100% are PI positive at 100 µM 9S1R.
This result is consistent with the effects of 100 µM 9S1R (2h time point) on cellular ATP and cell survival. But
the 2h time point is too short for an apoptotic process, and the drop in ATP level also contradicts and apoptotic
model of cell death. This response is also not typical of necrosis, since cell swelling is not observed.
4. Discussion
4.1 Solubilization of PolyArg peptides in trehalose
The original Nullomer peptides 9 (NWMWC), 9S1 (WCMNW) and 124 (WFMHW) are composed of two
types of amino acids: MWF (hydrophobic non polar), and CNH (polar but uncharged). They are insoluble in
water, and though they are initially soluble in absolute ethanol, after mixing with culture medium they
precipitate. We solubilized the PolyArg conjugated peptides in 1M trehalose (though the NulloPs without
PolyArg are insoluble in 1M trehalose). The solubilization process was instantaneous, and PolyArg conjugated
peptides remain stable in solution at room temperature. Trehalose has a water replacing capacity and most likely
surrounds the hydrophobic peptides with a carbohydrate coat [30]. It has been used extensively in the
formulation of therapeutic proteins, because of its qualities as a protein-stabilizer [25]. This is the first time to
our knowledge that a CPP conjugated cargo has been solubilized in trehalose. While others [52] report that an
R5 tail is not sufficient for cell penetration, the conjugation of an R5 tail to our peptides 9, 9S1 and 124,
facilitates solublization in trehalose.
4.2 PolyArgNulloPs potential for cancer treatment
The treatment of human cancer is not a single drug therapy. A cocktail of drugs aimed at different targets in
cancer cells is used to avoid drug resistance. Potential drugs against cancer are characterized by their IC-50,
which is the dose that inhibits the growth of 50% of the cell population exposed to the drug. Protocols have
been established in the USA by the NCI/NIH [9,40], and in Japan [55], for testing potential new drugs against a
panel of cell lines. The current protocols expose cancer cells to drugs for 48h [57] or 72h [40], followed by cell
viability assays. It is noteworthy that the screening systems available like the NCI-60 panel of cancer cells
[9,40], the JFCR39 panel of 39 cell lines used in Japan [55] or the recently established CMT1000 (Center for
Molecular Therapeutics 1000) panel consisting of 1200 cancer cell lines [46], do not include normal cells as
controls. The differential sensitivity of cancer cells and normal cells, to cancer drugs, is a complex area. In some
studies, normal cells are not sensitive at all to cancer drugs [38]. In other studies, the response of normal cells to
cancer drugs depends on the culture protocol: contact inhibited quiescent 3T3 fibroblasts are not sensitive (to
cisplatin and etoposide) [24], while exponentially dividing 3T3 fibroblasts [24] and MCF-10A (normal human
mammary epithelial cell line) are sensitive [8].
The results presented here include an analysis of the PolyArgNulloPs differential IC-50 evolution in normal
and cancer cells. LnCap and MDA-MB-231 cells were included in our study because they represent,
respectively, the most frequent cancer in men (prostate cancer) and women (breast cancer). We looked at the
killing potential of PolyArgNulloPs at 3 different time points to assess their cytotoxicity and effect on growth.
As shown in Table 1, the IC-50 evolution of 9R and 9S1R in LnCap and MDA-MB-231 demonstrates that these
cancer lines have an increasing sensitivity to our peptides over time, while the normal cell lines have a
decreasing sensitivity. The LnCap IC-50 of 9R starts at 44 ±2.5 µM at 2h, and falls to 28 ±1.6 µM by 48h. The
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LnCap IC-50 for 9S1R starts 26 ±1.3 µM at 2h, and drops to 8 ±0.5 µM at 48h. The same pattern is seen with
MDA-MB-231 cells, HUT102 cells and J774A.1 cells. For normal cells like PCS and HMEC, the opposite
pattern is seen. The PCS IC-50 of 9R starts at 28 ±1.1 µM at 2h, and reaches 35±1.3 µM at 48h. For HMEC
cells, the IC-50 for 9R starts at 20 ±0.8 µM at 2h, and reaches 34 ±1.2 µM at 48h. This differential pattern of
the IC-50 evolution for our peptides shows clearly that normal cells, although inhibited by our peptides can
recover, while the sensitivity of cancer cells increases with time. Other researchers have found similar patterns
of increased sensitivity for taxol and other drugs [18,32,33,35,44]. Unfortunately, these early observations were
not investigated further, and these studies failed to include normal cells [18,32,33,35,44]. The parallel
evaluation of cancer cells and normal cells in regard to their sensitivity to cancer drugs is important, because the
side effects of cancer drugs on normal cells are a major clinical issue. To our knowledge the differential
evolution of IC-50 in cancer cells versus normal cells is assessed for the first time here. This comparison of
normal versus cancer cell sensitivity over time, may be useful to future screening efforts.
4.3 The lack of effects of 9R, 9S1R and 124R on melanoma B16 cells
It is surprising that 9R and 9S1R at 100µM, even at time points up to 96h, have no effect on the growth of
melanoma B16 cells. The resistance mechanism(s) of B16 cells to PolyArgNulloPs are not known. It has been
reported previously that CPPs other than R5 are more efficient at delivering lethal drugs in melanoma cell lines
(Bowes melanoma cells [20], and SKMel-37 melanoma cells [15]). Changing the CPP in future studies of the
NulloPs may yield better results.
4.4 Comparison of the killing mechanisms of 9R and 9S1R
The analysis of our results support the simple statement that peptides 9R and 9S1R have devastating effects
on the mitochondria (as evidenced by their changes in cellular ATP, MMP, and ROS production), and
consequently on cell growth. These effects are similar to the effects of amyloid beta peptide on nervous cells in
Alzheimer disease, where the amyloid beta peptides are imported into mitochondria [22]. The CPP conjugated
peptides do not cross the mitochondrial membrane [43], however the mitochondrial outer membrane has a
porine protein which is permeable to compounds up to 5000 Da. Our PolyArgNulloPs are in the 1500 Da range,
so it is possible that 9R accumulates in the mitochondria, a hypothesis that is under investigation in our lab. Our
results, especially the contrast in effects of 9R and 9S1R on cellular ATP, suggest that 9S1R targets nonmitochondrial cytosolic metabolism, whereas 9R attacks the mitochondria. 9S1R (50 µM) almost completely
shuts down the ATP production in LnCap and MDA-MB-231 cells. We know that the respiratory chain in the
mitochondria is the main source of ATP production in the cells, but glycolysis is important to cancer cell
metabolism. The dramatic effect of 9S1R on ATP production (greater than sodium azide) may be caused by an
inhibition of cellular glycolysis which automatically shuts down the respiratory chain in the mitochondria.
Therefore, 9S1R is a candidate for the new metabolic strategy of treating cancer through glycolysis inhibition
[54] and ATP depletion [28]. Peptide 9R also lowers cellular ATP content by attacking the mitochondria.
4.5 Successful first use of the nullomer approach for drug development
As with any in vitro drug screening, we realize that our results will need to be assessed in animal models.
The treatment of cancer is based on the log-kill hypothesis established in 1970 by Skipper et al. [47]. Basically,
this hypothesis states that at a certain dose, a cancer drug kills only a fraction of a tumor cell population. This
leads to treatment cycles, in which every cycle enriches the proportion of resistant cells. So the results obtained
in vitro for a single dose, may not match the results in vivo. Another difference between cell culture and animal
studies is that in vitro we start with a small number of cells, and see if a cancer drug can inhibit the growth of
that small population; but in vivo studies usually begin with established tumors. As the tumor grows in volume,
the fraction of cycling cells diminishes; and as the log-kill hypothesis states, the response to cancer drugs
declines. For this reason, cancer therapy uses a cocktail of drugs to attack multiple cellular targets. The
relatively high doses used in this paper should not disqualify NulloPs as possible drugs for cancer treatment.
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Cancer treatment is always a combination of drugs rather than a single drug, and our next phase of research is
looking at possible combination drug treatments. The protocols based on the log-kill hypothesis have been
improved recently by a new strategy focusing on the amount of drug per unit time, or dose intensity. This
approach is based on high dose drug pulses rather than on a continuous regimen [19]. The first screening of
potential anticancer drugs usually focuses a single drug treatment, and we have shown that our PolyArgNulloPs
kill cancer cells by targeting mitochondrial health and ATP production. We do not envision their use as single
anticancer drugs, but rather combined with other drugs. It is important to note that the difference in sensitivity
was measured in rapidly growing, rather than quiescent cell cultures. We are currently studying the differential
effects of NulloPs on cancer cells, versus dividing and quiescent normal cells.
5. Conclusion
We present here the first drug candidates produced by nullomer research. The bio-informatic approach
which identified the NulloPs was based on the idea that rare or absent short sequences may be enriched for toxic
or problematic peptides. We have shown that the differential effects of PolyArgNulloPs on cancer cells and
normal cells indicate that these new peptides should be investigated and optimized for cancer treatment.

Fig 1. Scanning electron microscopy of untreated and nullomer (124, 9R, 9S1) treated LnCap and MDA-MB231 cells.
(A-H) lower magnification views. (a-h) higher magnification views. (A,a, B,b) Untreated control LnCap and
MDA-MB-231 cells respectively. (C,c, D,d) LnCap and MDA-MB-231 cells, respectively, treated with
nullomer 124 (100 µM for 48 hr.). SEM examination of overall cell growth and membrane integrity after
treatment with nullomer 124 are unchanged from untreated control cells. (E,e, F,f) LnCap and MDA-MB-231
cells respectively treated with peptide 9R (100 µM for 48 hr.); overall cell growth markedly reduced compared
with untreated control cell cultures. Cytopyknosis and membrane blebs appear (e, lower right and F,f). (G,g,
H,h) LnCap and MDA-MB-231 cells, respectively, treated with peptide 9S1 (100 µM for 48 hr.); overall cell
numbers less noticeably reduced than in cells treated with peptide 9R, but show widespread severe membrane
damage consistent with necrosis. Scale bars = 50 µm (A-H), 25 µm (a-h).
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Fig. 2. PolyArgNulloPs effects on cellular ATP level. Cells (3000/well) were seeded in 96 well plates (white
plates from Nunc). After 24 h incubation, peptides 9R, 9S1R and 124R were added to the wells. Control
conditions included untreated cells, and 100mM sodium azide. At 2h, 24h, and 48h a single reagent Cell Titer
GlowTM (Promega,Madison) was added to the wells (v/v ratio with media), and ATP determined with emission
reading using the SynergyMx plate reader. The statistical analysis was done with the GraphPadPRISM*.	
  
Results are as mean ± SE (standard error) of three different experiments. NS, not significant. **∗p<0.05,
∗∗p<0.01, ∗∗∗p<0.001
(A), LnCap, at a 2h, b 24h, and c 48h. (B) MDA-MB-231 at a 2h, b 24h, and c 48h.
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Fig. 3. PolyArgNulloPs effects on MMP. LnCap cells (3000/well) were seeded in 96 well plates (white plates
from Nunc). After 24 h incubation peptides 9R, 9S1R and 124R were added to the wells. Control conditions
included untreated cells, and H2O2 (0.01%) treated cells. At 24h, 50 µl of mitochondria staining solution (Mito
Health) was added per well (following manufacturer’s protocol) and incubated for 30 mn. Relative fluorescence
was measured in BioTek Synergy plate reader. The statistical analysis was done with the GraphPadPRISM*.	
  
Results are as mean ± SE (standard error) of three different experiments.
NS, not significant. *p<0.05, ***p<0.01, ***p<0.001
(a), LnCap, at 24h. (b) MDA-MB-231, at 24h.
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Fig. 4. PolyArgNulloPs effects on ROS production. LnCap cells (3000/well) were seeded in 96 well plates
(white plates from Nunc). After 24 h incubation peptides 9R, 9S1R and 124R were added to the wells. Control
conditions included untreated, and H2O2 (0.01%) treated cells. After 2h incubation, cells were treated with
MitoSox red reagent for 10 mn, then washed with PBS, and the plate read in the microplate BioTek Synergy
reader. The statistical analysis was done with the GraphPadPRISM*.	
  Results are as mean ± SE (standard error) of
three different experiments NS, not significant. *p<0.05, ***p<0.01, ***p<0.001
(a), LnCap, at 2h. (b) MDA-MB-231, at 2h.

(a), LnCap

a. LnCap 2h

***

800

***

510-580nm

600
400

**

*

ns

ns

200

9S1R(50µM)

9S1R(100µM)

9S1R(20µM)

9S1R(10µM)

9R(50µM)

9R(100µM)

9R(20µM)

9R(10µM)

124R(50µM)

124R(100µM)

124R(20µM)

124R(10µM)

H2O 2 (0.01%)

Untreated Cells

0

(b) MDA-MB-231

b. MDA-MB-231 2h
1000
800

510-580nm

***

***

600
400

**

200

ns

ns

ns

9S1R(100µM)

9S1R(50µM)

9S1R(20µM)

9R(100µM)

9S1R(10µM)

9R(50µM)

9R(20µM)

9R(10µM)

124R(100µM)

124R(50µM)

124R(20µM)

124R(10µM)

H2O 2 (0.01%)

Untreated Cells

0

	
  

14	
  
NOTICE: this is the author's version of a work that was accepted for publication in Peptides. Changes resulting from the publishing process, such as peer review, editing, corrections,
structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication.
A definitive version was subsequently published in Peptides, 2012. DOI: 10.1016/j.peptides.2012.09.015

Fig. 5. Hemolytic activity of PolyArgNulloPs. RBCs collected from healthy donors were diluted 1:10 in PBS,
and peptides 9R, 9S1R and 124R were added. Control conditions included PBS, and 1%Triton X-100. After 24h
incubation at 37ºC with 100 rpm shaking, RBCs were centrifuged and the supernatant collected in a 96 well
plates. Absorbance was determined at 405 nm. The hemolytic activity in % was calculated using the formula:
Hemolytic activity in %={[ASample-AControl]/[ATotal-AControl]}x100
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Table 1. IC-50 (µM) Evolution. The IC-50 were calculated from the raw data of MTT readings at 570nm using
the GraphPad PRISM* version 5.03. Dose response curves generated by non linear regression with GraphPad
PRISM* were used to determine the IC-50s. Basically the x values from the y=f(x) function were transformed
into Log10 scale. The y values normalized between 0% and 100% effects and IC-50 calculated. All results are
expressed as mean ± SE (standard error). A p-value of less than 0.05 was considered statistically significant.
>100* when there is no effects on cell growth for doses range used (10-100 µM).
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Table 1: IC-50 (µM) Evolution

Cell Line

LnCap

MDA-MB-231

PCS

HMEC

HUT102

J774A.1

Time (h)

Peptide

9R

9S1R

124R

2h

44±2.5

26±1.3

>100*

24h

23±1.2

9±0.6

>100

48h

28±1.6

8±0.5

>100

2h

39±1.8

18±0.8

>100

24h

29±1.7

12±0.4

>100

48h

16±0.9

10±0.3

>100

24h

28±1.1

26±1.2

>100

48h

35±1.3

22±0.9

88±2.3

24h

20±0.8

17±0.8

29±1.1

48h

34±1.2

19±0.6

46±2.2

2h

93±2.3

38±1.4

>100

24h

39±1.1

43±1.4

>100

48h

37±2.5

43±3.2

>100

72h

36±1.8

45±2.2

>100

96h

25±1.6

36±1.4

>100

24h

47±2.5

26±1.3

66±3.5

96h

12±0.7

17±1.2

31±1.5
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Suppl.R1. Effect of PolyArgNulloPs on cell growth. 3000-5000 cells/well were seeded in 96-well plates. After
24h incubation, peptides 9R, 9S1R and 124R were added to the wells. Control conditions included untreated,
and H2O2 (0.01%) treated cells. Viability of cells was determined with an MTT assay at different time points.
(A) LnCap at a 2h, b 24h, and c 48h. (B) MDA-MB-231, at a 2h, b 24h, and c 48h. (C) B16, at a 2h, b 96h. (D)
HUT 102, at a 2h, b 48h, c 72h and d 96h. (E) J774A.1, at a 2h, b 48h, c 72h and d 96h. (F) WI-38, at a 24h, b
48h. (G) PCS, at a 24h, b 48h. (H) HMEC, at a 24h, b 48h.	
  Results are as mean ± SE (standard error) of three
different experiments. NS, not significant. *∗p<0.05, **∗∗p< 0.01,****∗∗∗p<0.001
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9S1R(75µM)
9S1R(100µM)

a. B16 2h
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570nm

0.4
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0.6

Untreated Cells
H2O 2 (0.01%)
124R(5µM)
124R(10µM)
124R(20µM)
124R(50µM)
124R(75µM)
124R(100µM)
9R(5µM)
9R(10µM)
9R(20µM)
9R(50µM)
9R(75µM)
9R(100µM)
9S1R(5µM)
9S1R(10µM)
9S1R(20µM)
9S1R(50µM)
9S1R(75µM)
9S1R(100µM)

0.2

ns

570nm

Untreated Cells
H2O 2 (0.01%)
124R(5µM)
124R(10µM)
124R(20µM)
124R(50µM)
124R(75µM)
124R(100µM)
9R(5µM)
9R(10µM)
9R(20µM)
9R(50µM)
9R(75µM)
9R(100µM)
9S1R(5µM)
9S1R(10µM)
9S1R(20µM)
9S1R(50µM)
9S1R(75µM)
9S1R(100µM)

0.8

Untreated Cells
H2O 2 (0.01%)
124R(5µM)
124R(10µM)
124R(20µM)
124R(50µM)
124R(75µM)
124R(100µM)
9R(5µM)
9R(10µM)
9R(20µM)
9R(50µM)
9R(75µM)
9R(100µM)
9S1R(5µM)
9S1R(10µM)
9S1R(20µM)
9S1R(50µM)
9S1R(75µM)
9S1R(100µM)

Untreated Cells
H2O 2 (0.01%)
124R(5µM)
124R(10µM)
124R(20µM)
124R(50µM)
124R(75µM)
124R(100µM)
9R(5µM)
9R(10µM)
9R(20µM)
9R(50µM)
9R(75µM)
9R(100µM)
9S1R(5µM)
9S1R(10µM)
9S1R(20µM)
9S1R(50µM)
9S1R(75µM)
9S1R(100µM)

570nm

(C) B16
b. B16 96h

ns

2

1

0

***

(D) HUT 102
b. HUT102 48h
c. HUT102 72h

0.6

***

***
0.4

ns
***
***

***

0.0

d. HUT102 96h

**
ns
***

0.2

***

0.0
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***
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570nm
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ns
ns

***

Untreated Cells
H2O 2 (0.01%)
124R(5µM)
124R(20µM)
124R(50µM)
124R(75µM)
124R(100µM)
9R(5µM)
9R(20µM)
9R(50µM)
9R(75µM)
9S1R(100µM)
9S1R(5µM)
9S1R(20µM)
9S1R(50µM)
9S1R(75µM)
9S1R(1000µM)

0.2

*
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Untreated Cells
H2O 2 (0.01%)
124R(5µM)
124R(20µM)
124R(50µM)
124R(75µM)
124R(100µM)
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9R(20µM)
9R(50µM)
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9S1R(50µM)
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9S1R(1000µM)

0.10

570nm

Untreated Cells
H2O 2 (0.01%)
124R(5µM)
124R(20µM)
124R(50µM)
124R(75µM)
124R(100µM)
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9R(20µM)
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9S1R(5µM)
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9R(10µM)
9R(20µM)
9R(40µM)
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9R(100µM)
9S1(10µM)
9S1(20µM)
9S1(40µM)
9S1(60µM)
9S1(100µM)

Untreated Cells
H2O 2 (0.01%)
124R(5µM)
124R(20µM)
124R(500µM)
124R(75µM)
124R(1000µM)
9R(5µM)
9R(20µM)
9R(50µM)
9R(75µM)
9R(100µM)
9S1R(5µM)
9S1R(20µM)
9S1R(50µM)
9S1R(75µM)
9S1R(100µM)

570nm

(E) J774A.1
a. J774A.1 2h

b. J774A.1 24h

0.25

ns

ns

a. WI-38 24h
0.5

ns
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ns

ns

0.4

0.3

ns

0.20

**

0.15

***

d. J774A.1 96h

ns

1.0

***
***

0.5

***

0.0

(F) WI-38
b. WI-38 48h

ns
ns

*
***

0.1

***

0.0
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Suppl.R2. PolyArgNulloPs induced cell death (Live/Dead assay). LnCap cells (3000/well) were seeded in 96
well plates (white plates from Nunc). After 24 h incubation peptides 9R, 9S1R and 124R were added to the
wells. Control conditions included untreated, and H2O2 (0.01%) treated cells. After 2h incubation, Hoechst
33342 and PI dyes were added to the cells, and fluorescent images were taken with a Zeiss axiovert 40
microscope (Oberkochen, Germany) with SPOT imaging camera (Sterling Heights, MI). (A) LnCap. (B) MDAMB-231
(A) Ln Cap

LnCap Untreated

LnCap 124R 100 µM

LnCap 9R 10 µM

LnCap 9R 50 µM

LnCap 9S1R 10 µM

LnCap H202 0.01%

LnCap 9R 100 µM

LnCap 9S1R 50 µM

LnCap 9S1R 100 µM
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(B) MDA-MB-231

MDA-MB-231 Untreated

MDA-MB-231 124R 100 µM

MDA-MB-231 9R 10 µM

MDA-MB-231 9R 50 µM

MDA-MB-231 9S1R 10 µM

MDA-MB-231 9S1R 50 µM

MDA-MB-231 H202 0.01%

MDA-MB-231 9R 100 µM

MDA-MB-231 9S1R 100 µM

23	
  
NOTICE: this is the author's version of a work that was accepted for publication in Peptides. Changes resulting from the publishing process, such as peer review, editing, corrections,
structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication.
A definitive version was subsequently published in Peptides, 2012. DOI: 10.1016/j.peptides.2012.09.015

References
[1] Acquisti C, Poste G, Curtiss D, Kumar S. Nullomer: really a matter of natural selection? PLoS One 2007;
2: e1022.
[2]

Alileche A. Interleukin-2 and cancer: critical analysis of results, problems and expectations
Hypotheses 2003; 60: 202-208.

Med

[3] Alileche A, Serfass ER, Muehlbauer SM, Porcelli SA, Brojatsch J. Anthrax lethal toxin mediated killing of
human and murine dendritic cells impairs the adaptive immune system PLoS Pathogens 2005; 1: e19.
[4] Alileche A, Squires RC, Muehlbauer SM, Lisanti MP, Brojatsch J. Mitochondrial impairment is a critical
event in anthrax lethal toxin induced cytolysis of murine macrophages Cell Cycle 2006; 5:100-106.
[5] Bari K, Petrik J, Rumora L. “Biochemistry of apoptotic cell death” Acta Pharm 2003; 53: 151–164.
[6] Bensinger SJ, Christofk HR. Review: New aspects of the Warburg effect in cancer cell biology Sem in
Cell & Devlpt Biol 2012; 23:352-361.
[7] Capone G, Novello G, Fusano C, Trost B, Bickis M, Kusalik A et al. The oligodeoxynucleotide sequences
corresponding to never expressed peptide motifs are mainly located in the non coding strand BMC
Bioinformatics 2010; 11: 383.
[8] Cyr L, Langler R, Lavigne C. Cell cycle arrest and apoptosis responses of human breast epithelial cells to
the synthetic organosulfur compound p-Methoxyphenyl p-Toluenesulfonate Anticancer Res 2008; 28:
2753-2764.
[9] Dhar S, Nygren P, Csoka K, Botling J, Nilsson K. Anti cancer drug characterization using a human cell
line panel representing defined types of drug resistance Br J of Cancer 1996; 74: 888-89.
[10]

Droin N, Hendra JB, Ducoroy P, Solary E. Human defensins as cancer biomarkers and antitumor
molecules J Proteomics 2009; 72: 918-927.

[11] D’Souza GMG, Wagle MA, Saxena V, Shah A. Approaches for targeting mitochondria in cancer therapy
Bioch Biophys Acta 2011; 1807: 589-696.
[12] Fantin VR, Leder P. Mitochondriotoxic compounds for cancer therapy Oncogene 2006; 25: 4787-4797.
[13] Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B et al. Tat mediated delivery of heterologous
proteins into cells PNAS US 1994; 91; 664-668.
[14]

Ferlay J, Bray F, Pisani P, Parkin DM. eds GLOBOCAN 2002: Cancer Incidence, Mortality and
Prevalence Worldwide. Lyon France IARC Press 2004.

[15] Fischer M, Waizeneggar T, Kohler K, Brock R. A quantitative validation of fluorophore-labelled cellpermeable peptide conjugate Biochim Biophys Acta 2002; 1564: 365-374.
[16]

Fulda S, Kroemer G. Mitochondria as therapeutic targets for the treatment of malignant disease
Antioxidants& Redox Signaling 2011; 15: 2937-2949.

[17] Garcia SP, Pinho AJ. Minimal absent words in four human genome assemblies PLoS One 2011; 6:
e29344.
[18] Georgiadis MS, Russell EK, Gazdar AF, Johnson BE. Paclitaxel cytotoxicity against human lung cancer
cell lines increases with prolonged exposure durations Clin Cancer Res 1997; 3: 49-44.
24	
  
NOTICE: this is the author's version of a work that was accepted for publication in Peptides. Changes resulting from the publishing process, such as peer review, editing, corrections,
structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication.
A definitive version was subsequently published in Peptides, 2012. DOI: 10.1016/j.peptides.2012.09.015

[19] Hagemeister FB. Treatment of relapsed aggressive lymphomas: regimen with and without high dose
therapy and stem cell rescue Cancer Chemother Pharmacol 2002; 49 (suppl.1): S13-S20
[20] Hallbrink M, Floren A, Elmquist A, Pooga M, Bartfai T, Langel U. Cargo delivery kinetics of cellpenetrating peptides Biochim Biophys Acta 2001; 1515: 101-109.
[21] Hampikian G, Andersen T. “Absent Sequences: Nullomers and Primes” Pac Symp Biocomput 2007; 12:
355-366.
[22] Hansson Petersen CA, Alikhani N, Behbani H, Wiehager B, Pavlov PF. Alafuzoff I, et al. The amyloid
beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial
cristae PNAS US 2008; 105: 13145-13450.
[23] Hilchie AL, Douctte CD, Pinto DM, Patrzykat A, Douglas S. Hoskin DW. Pleurocidin-family cationic
antimicrobial peptides are cytolytic for breast carcinoma and prevent growth of tumor xenografts Breast
Cancer Res 2011; 13:R102.
[24] Hyot MT, Palchaudhuri R, Hergenrother PJ. Cribrostatin 6 induces death in cancer cells through a
reactive oxygen spieces (ROS)-mediated mechanism Invest New Drugs 2011; 29: 562-573.
[25] Izutsu KI. Stabiliztion of therapeutic proteins by chemical and physical methods Methods In Molecular
Biology Vol 308, Humana Press Eds 2005 Chapter 22: p287-292.
[26] Koji I, Hiroyuki T. Protective Effect of Benidipine Against Sodium Azide-Induced Cell Death in Cultured
Neonatal Rat Cardiac Myocytes J Pharmacol Sci 2003; 93: 163 –170.
[27] Kondo T, Setoguchi T, Tga T. Persistence of a small subpopulation of cancer stem like cells in the C6
glioma cell line PNAS US 2004; 101: 781-786.
[28] Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torberson MS, et al. Advanced cancers: eradication
in all cases using 3-bromopyruvate therapy to deplete ATP Biochem Biophs Res Comm 2004, 324: 269275.
[29] Kroemer G. Introduction: mitochondrial control of apoptosis Biochimie 2002; 84: 100-104.
[30] Kumar M, Roy J, Roy I. Effects of trehalose on protein structure Protein Science 2008; 18: 24-36.
[31] Lucchese G, Stufano A, Trost B, Kusalik A, Kanduc D. Peptidology: short amino acids modules in cell
biology and immunology Amino Acids 2007; 33: 703-707.
[32] Lopes NM, Adams EG, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycle effects of Taxol on human
and hamster ovarian cell lines Cancer Chemother Pharmacol 1993; 32: 235-242.
[33] Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Venzon D, et al. Cytotoxic studies of paclitaxel
(Taxol) in human tumor cell lines Br J Cancer 1993; 68: 1104-1109.
[34] Melikov K, Chernormordik V. Arginine rich cell penetrating peptides: from endosomal uptake to nuclear
delivery Cell Mol Life Sci 2005; 62: 2739-2749.
[35] Min-Wen H, Ke-Zuo H, Yun-Peng L, Yuan Y. Effect of staurosporine on cycle human gastric cancer cell
World J Gastroenterol 2004; 10: 161-166.
[36] Mishra A, Gordon V, Yang L, Coridan R, Wong G. HIV TAT forms pores in membranes by inducing
saddle-splay curvature: potential role of bidentate hydrogen bonding Angew Chem Int Ed Engl 2008; 47:
2986-2989.
25	
  
NOTICE: this is the author's version of a work that was accepted for publication in Peptides. Changes resulting from the publishing process, such as peer review, editing, corrections,
structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication.
A definitive version was subsequently published in Peptides, 2012. DOI: 10.1016/j.peptides.2012.09.015

[37]

Nakase I, Takeuchi T, Tanaka G, Futaki S. Methodological and cellular aspects that govern the
internalization mechanisms of arginine rich cell penetrating peptides Advanced Drug Delivery Rev 2008;
60: 598-607.

[38] Nor I’zzah W, Zain VM, Rahmat B, Othman F, Yun Hin Yap T. Antiproliferative properties of clausine-B
against cancer cell lines Malaysian J of Medical Sciences 2009; 16: 31-36.
[39] Papo N, Shai Y. Host defense peptides as new weapons in cancer treatment Cell Molec Life Sci 2005;
62: 784-790.
[40] Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, et al. Display and analysis of
patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and
COMPARE algorithm J Natl Cancer Inst 1989; 81: 1088-1092.
[41] Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment Current
Med Chem 2006; 13: 1859-1875.
[42] Reches M, Porat Y, Gazit E. “Amyloid Fibril Formation by Pentapeptide and Tetrapeptide Fragments of
Human Calcitonin” J of Biol Chem 2002; 277: 35475–35480.
[43] Ross MF, Filipovska A, Smith RAJ, Gait MJ, Murphy MP. Cell penetrating peptides do not cross
mitochondrial membranes even when conjugated to a lipophilication: evidence against direct passage
through phospholipid bilayers Biochem J 2004; 383: 45-468.
[44] Rowinsky EK, Donehower RC, Jones RC, Tucker RW. Microtubule changes and cytotoxicity in leukemic
cell lines treated with Taxol Cancer Res 1988; 48: 4093-4100.
[45] Schmidt N, Mishra A, Lai GH, Wong GCL. Arginine rich cell penetrating peptides FEBS Letters 2010;
584: 1806-1813.
[46] Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of
candidate anticancer agents Nature Rev Cancer 2010; 10:241-252.
[47] Skipper HE, Shabel FM Jr, Mellett HH, Brockman RW. Implications of biochemical, cytokinetic,
pharmacologic and toxicolgic relationships in the design of optimal therapeutic schedules Cancer
Chemother Rep 1970; 54: 431-450.
[48] Somalarczyk R, Cichon T, Kamyzs W, Glowala-Kosinska M, Szydlo A. Lukasz S, et al. Anticancer
effects of CAMEL peptide Laboratory Invest 2010; 90: 940-952.
[49] Steinstraesser L, Hauk J, Schubert C, Al-Benna S, Stricker I, Hatt H, et al. Supression of soft tissue
sarcoma growth by a host defense like lytic peptide PLoS One 2011; 6: e18321.
[50] Tang C, Shao X, Sun B, Huang W, Qin F, Chen Y et al. Anticancer mechanism of peptide P18 in human
leukemia K562 cells Org Biomol Chem 2010; 8: 984-987.
[51] Vives E, Brodin P, Lebleu B. A truncated HIV-1 TAT protein basic domain rapidly translocates through
the plasma membrane and accumulates in the cell nucleus J Biol Chem 1997; 272: 16010-16017.
[52] Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis,
and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters PNAS
US 2000; 97: 13003-13008.

26	
  
NOTICE: this is the author's version of a work that was accepted for publication in Peptides. Changes resulting from the publishing process, such as peer review, editing, corrections,
structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication.
A definitive version was subsequently published in Peptides, 2012. DOI: 10.1016/j.peptides.2012.09.015

[53] Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system Virulence
2010; 1: 440-464.
[54] Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L. Bhalla KN, et al. Inhibition of glycolysis in cancer cells:
a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia
Cancer Res 2005; 65: 613-621.
[55]

Yamori T. Panel of human cancer cell lines provides valuable database for drug discovery and
bioinformatics Cancer Chemother Pharmacol 2003; 52 (Suppl. 1): S74-S79.

[56] Yang D, Lin ZH, Tewary P, Chen Q, De La Rosa G. Oppenheim JJ. Defensin participation in innate and
adaptive immunity Curr Pharm Dis 2007; 13: 3131-3139.
[57] Zhang P, Gao WY, Turner S, Ducatman BS. Gleevec (STI-571) inhibits lung cancer cell growth (A549)
and potentiates the cisplatin effect in vitro BMC Molecular Cell 2003; 2: 1-9.

Author Contributions:
Abdelkrim Alileche-Devised solubility protocols, designed and performed experiments, analyzed results, and
was the lead author in writing the paper.
Jayita Goswami-Designed and performed of experiments, analyzed results, contributed in writing the paper.
William Bourland-SEM preparation, imaging and analysis.
Michael Davis-Contributed to experimental design and analysis of results.
Greg Hampikian-Devised nullomer approach, designed experiments, analyzed results, contributed in writing
paper.

Acknowledgments: The authors are indebted to Celeste Bolin for her assistance in analysis, and comments on
the research.
Funded by: the Defense Threat Reduction
Agency under contract number W81XWH-07-1-0004, DNA Safeguard

27	
  
NOTICE: this is the author's version of a work that was accepted for publication in Peptides. Changes resulting from the publishing process, such as peer review, editing, corrections,
structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication.
A definitive version was subsequently published in Peptides, 2012. DOI: 10.1016/j.peptides.2012.09.015

